In vitro cytotoxicity of zoledronate (nitrogen-containing bisphosphonate: NBP) and/or etidronate (non-NBP) in tumour cells and periodontal cells

Archives of Oral Biology

Volumn 58, Issue 6, 2013, Pages 628-637

  Tanaka, Yukinori ^a   Nagai, Yasuhiro ^a   Dohdoh, Mina ^a   Oizumi, Takefumi ^a   Ohki, Akiko ^a   Kuroishi, Toshinobu ^a   Sugawara, Shunji ^a   Endo, Yasuo ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Bisphosphonate; Cytotoxicity; Etidronate; Zoledronate

Indexed keywords

2 (2 METHOXY 4 NITROPHENYL) 3 (4 NITROPHENYL) 5 (2,4 DISULFOPHENYL) 2H TETRAZOLIUM MONOSODIUM SALT; 2-(2-METHOXY-4-NITROPHENYL)-3-(4-NITROPHENYL)-5-(2,4-DISULFOPHENYL)-2H TETRAZOLIUM MONOSODIUM SALT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; COLORING AGENT; DIAGNOSTIC AGENT; DRUG DERIVATIVE; ETIDRONIC ACID; FITC ANNEXIN A5; FITC-ANNEXIN A5; FLUORESCEIN ISOTHIOCYANATE; FLUORESCENT DYE; IMIDAZOLE DERIVATIVE; LIPOCORTIN 5; PROPIDIUM IODIDE; TETRAZOLIUM; ZOLEDRONIC ACID;

ACUTE MONOCYTIC LEUKEMIA; ADENOCARCINOMA; APOPTOSIS; ARTICLE; CELL CULTURE; CELL SURVIVAL; CEMENTUM; CULTURE TECHNIQUE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; ENDOTHELIUM CELL; FIBROBLAST; GINGIVA; HUMAN; MESENCHYMAL STROMA CELL; PATHOLOGY; PERIODONTAL LIGAMENT; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ADENOCARCINOMA; ANNEXIN A5; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; CARCINOMA, SQUAMOUS CELL; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; COLORING AGENTS; DENTAL CEMENTUM; DIPHOSPHONATES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ETIDRONIC ACID; FIBROBLASTS; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; GINGIVA; HUMANS; IMIDAZOLES; LEUKEMIA, MONOCYTIC, ACUTE; MESENCHYMAL STROMAL CELLS; PERIODONTAL LIGAMENT; PROPIDIUM; TETRAZOLIUM SALTS; UMBILICAL VEINS;

RODENTIA;

EID: 84877582711     PISSN: 00039969     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archoralbio.2012.11.010     Document Type: Article

References (42)

1. A.D. Geddes, S.M. D'Souzaa, F.H. Ebetino, and K.J. Ibbotson Bisphosphonates: structure-activity relationships and therapeutic implications J.N.M. Heersche, J.A. Kanis, Bone and mineral research vol. 8 1994 Elsevier Science BV Amsterdam 265 306
2. A.J. Roelofs, K. Thompson, S. Gordon, and M.J. Rogers Molecular mechanisms of action of bisphosphonates: current status Clinical Cancer Research 12 20 Pt 2 2006 6222s 6230s
3. S.L. Ruggiero, B. Mehrotra, T.J. Rosenberg, and S.L. Engroff Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases Journal of Oral and Maxillofacial Surgery 62 5 2004 527 534
4. S.B. Woo, J.W. Hellstein, and J.R. Kalmar Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws Annals of Internal Medicine 144 10 2006 753 761
5. S. Adami, and N. Zamberlan Adverse effects of bisphosphonates. A comparative review Drug Safety 14 3 1996 158 170
6. H. Fleisch Bisphosphonates in bone disease: from the laboratory to the patient 4th ed. 2000 Academic Press San Diego
7. M. Pazianas, P. Miller, W.A. Blumentals, M. Bernal, and P. Kothawala A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics Clinical Therapeutics 29 8 2007 1548 1558
8. G.L. Plosker, and K.L. Goa Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease Drugs 47 6 1994 945 982
9. T. van Staa, L. Abenhaim, and C. Cooper Upper gastrointestinal adverse events and cyclical etidronate American Journal of Medicine 103 6 1997 462 467
10. S. Crépin, M.L. Laroche, B. Sarry, and L. Merle Osteonecrosis of the jaw induced by clodronate, an alkylbiphosphonate: case report and literature review European Journal of Clinical Pharmacology 66 6 2010 547 554
11. T. Oizumi, H. Funayama, K. Yamaguchi, M. Yokoyama, H. Takahashi, and M. Yamamoto Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs Journal of Oral and Maxillofacial Surgery 68 5 2010 1043 1054
12. K. Yamaguchi, T. Oizumi, H. Funayama, H. Kawamura, S. Sugawara, and Y. Endo Osteonecrosis of the jawbones in 2 osteoporosis patients treated with nitrogen-containing bisphosphonates: osteonecrosis reduction replacing NBP with non-NBP (etidronate) and rationale Journal of Oral and Maxillofacial Surgery 68 4 2010 889 897
13. M.A. Scheper, A. Badros, A.R. Salama, G. Warburton, K.J. Cullen, and D.S. Weikel A novel bioassay model to determine clinically significant bisphosphonate levels Supportive Care in Cancer 17 12 2009 1553 1557
14. Y. Endo, M. Nakamura, T. Kikuchi, H. Shinoda, Y. Takeda, and Y. Nitta Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo Calcified Tissue International 52 3 1993 248 254
15. R. Schenk, P. Eggli, H. Fleisch, and S. Rosini Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat Calcified Tissue International 38 6 1986 342 349
16. T. Oizumi, K. Yamaguchi, H. Funayama, T. Kuroishi, H. Kawamura, and S. Sugawara Necrotic actions of nitrogen-containing bisphosphonates and their inhibition by clodronate, a non-nitrogen-containing bisphosphonate in mice: potential for utilization of clodronate as a combination drug with a nitrogen-containing bisphosphonate Basic and Clinical Pharmacology and Toxicology 104 5 2009 384 392
17. S. Suri, J. Monkkonen, M. Taskinen, J. Pesonen, M.A. Blank, and R.J. Phipps Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity Bone 29 4 2001 336 343
18. H. Mönkkönen, S. Törmälehto, K. Asunmaa, R. Niemi, S. Auriola, and J. Vepsäläinen Cellular uptake and metabolism of clodronate and its derivatives in Caco-2 cells: a possible correlation with bisphosphonate-induced gastrointestinal side-effects European Journal of Pharmaceutical Sciences 19 1 2003 23 29
19. H. Agis, J. Blei, G. Watzek, and R. Gruber Is zoledronate toxic to human periodontal fibroblasts? Journal of Dental Research 89 1 2010 40 45
20. E. Corey, L.G. Brown, J.E. Quinn, M. Poot, M.P. Roudier, and C.S. Higano Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer Clinical Cancer Research 9 1 2003 295 306
21. T. Hiraga, A. Myoui, M.E. Choi, H. Yoshikawa, and T. Yoneda Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-β enhances bone metastases in breast cancer Cancer Research 66 4 2006 2067 2073
22. H.L. Neville-Webbe, M. Gnant, and R.E. Coleman Potential anticancer properties of bisphosphonates Seminars in Oncology 37 Suppl. 1 2010 S53 S65
23. P. Fournier, S. Boissier, S. Filleur, J. Guglielmi, F. Cabon, and M. Colombel Bisphosphonates inhibit angiogenesis in vitro and testosterone- stimulated vascular regrowth in the ventral prostate in castrated rats Cancer Research 62 22 2002 6538 6544
24. J. Wood, K. Bonjean, S. Ruetz, A. Bellahcène, L. Devy, and J.M. Foidart Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid Journal of Pharmacology and Experimental Therapeutics 302 3 2002 1055 1061
25. N. Caccamo, S. Meraviglia, G. Cicero, G. Gulotta, F. Moschella, and A. Cordova Aminobisphosphonates as new weapons for γδ T Cell-based immunotherapy of cancer Current Medicinal Chemistry 15 12 2008 1147 1153
26. Y. Endo, M. Shibazaki, K. Yamaguchi, M. Nakamura, and H. Kosugi Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate British Journal of Pharmacology 126 4 1999 903 910
27. H. Funayama, M. Ohsako, Y. Monma, H. Mayanagi, S. Sugawara, and Y. Endo Inhibition of inflammatory and bone-resorption-inhibitory effects of alendronate by etidronate Calcified Tissue International 76 6 2005 448 457
28. M. Kitagawa, H. Tahara, S. Kitagawa, H. Oka, Y. Kudo, and S. Sato Characterization of established cementoblast-like cell lines from human cementum-lining cells in vitro and in vivo Bone 39 5 2006 1035 1042
29. T. Minami, T. Kuroishi, A. Ozawa, H. Shimauchi, Y. Endo, and S. Sugawara Histamine amplifies immune response of gingival fibroblasts Journal of Dental Research 86 11 2007 1083 1088
30. E. Nemoto, S. Kanaya, M. Minamibuchi, and H. Shimauchi Cleavage of PDGF receptor on periodontal ligament cells by elastase Journal of Dental Research 84 7 2005 629 633
31. A.A. Reszka, J. Halasy-Nagy, and G.A. Rodan Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation Molecular Pharmacology 59 2 2001 193 202
32. J.C. Frith, J. Mönkkönen, G.M. Blackburn, R.G. Russell, and M.J. Rogers Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(β, γ-dichloromethylene) triphosphate, by mammalian cells in vitro Journal of Bone and Mineral Research 12 9 1997 1358 1367
33. A.M. Pabst, T. Ziebart, F.P. Koch, K.Y. Taylor, B. Al-Nawas, and C. Walter The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes-in vitro study Clinical Oral Investigations 16 1 2012 87 93
34. C. Walter, M.O. Klein, A. Pabst, B. Al-Nawas, H. Duschner, and T. Ziebart Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells Clinical Oral Investigations 14 1 2010 35 41
35. J. Mönkkönen, M. Taskinen, S.O. Auriola, and A. Urtti Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro Journal of Drug Targeting 2 4 1994 299 308
36. Y. Kobayashi, T. Hiraga, A. Ueda, L. Wang, M. Matsumoto-Nakano, and K. Hata Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice Journal of Bone and Mineral Metabolism 28 2 2010 165 175
37. A.C. Hirbe, A.J. Roelofs, D.H. Floyd, H.J. Deng, S.N. Becker, and L.G. Lanigan The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts Bone 44 5 2009 908 916
38. A.U. Ural, F. Avcu, M. Candir, M. Guden, and M.A. Ozcan In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells Breast Cancer Research 8 4 2006 R52
39. J.C. Frith, J. Mönkkönen, S. Auriola, H. Mönkkönen, and M.J. Rogers The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis Arthritis and Rheumatism 44 9 2001 2201 2210
40. M.J. Rogers, S. Gordon, H.L. Benford, F.P. Coxon, S.P. Luckman, and J. Monkkonen Cellular and molecular mechanisms of action of bisphosphonates Cancer 88 Suppl. 12 2000 2961 2978
41. J. Räikkönen, J.C. Crockett, M.J. Rogers, H. Mönkkönen, S. Auriola, and J. Mönkkönen Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro British Journal of Pharmacology 157 3 2009 427 435
42. J. Mönkkönen, H.M. Koponen, and P. Ylitalo Comparison of the distribution of three bisphosphonates in mice Pharmacology and Toxicology 66 4 1990 294 298